Generic Pharmaceuticals Pricing Antitrust Litigation

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

May 2026 Update

Filed in 2016 and centralized in the Eastern District of Pennsylvania, the Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724) remains one of the largest and most complex antitrust cases in the U.S. The litigation alleges that multiple generic drug manufacturers conspired to fix prices, allocate markets, and limit competition across hundreds of generic drugs.

Current Status (2026)

This case remains active and ongoing, with multiple tracks:

• Direct Purchasers (DPP): (Wholesalers and Distributors)

• Indirect Resellers (IRP): (Dispensers of Drugs including Hospitals and Independent Pharmacies)

• End Payors (EPP): (Consumers, Insurers, Third-Party Payors)

Key Developments:

The litigation has progressed with significant settlements already secured while key legal and procedural issues continue to be worked through across all tracks. The Court has certified certain classes and appeals are ongoing, particularly in cases involving drugs like clobetasol (used to treat skin conditions such as eczema and psoriasis) and clomipramine (used to treat obsessive-compulsive disorder), which are helping shape broader litigation strategy.

At the same time, bellwether cases and ongoing discovery efforts continue to define how damages are proven—especially for hospitals and resellers where pricing and reimbursement structures vary widely. Parallel federal and multi-state enforcement actions are also continuing alongside the MDL, adding another layer of complexity to how claims may ultimately be resolved and distributed.

Overall, while more than $1 billion in settlements has been reached or proposed, —including the recently filed $5.75 million Lupin Indirect Resellers settlement pending preliminary approval—the case remains actively developing, with future filing opportunities and additional recoveries still expected.

Settlement Progress

To date, the MDL has generated substantial settlement activity across multiple defendants and classes:

Total Recovery to Date

• ~$1.009 billion across MDL class settlements and proposed settlements

Settlement Activity by Claim Type

• Direct Purchasers (DPP): ~$457.3M

• End Payors (EPP): ~$533M

• Indirect Resellers (IRP): ~$12M (including the proposed Lupin settlement pending preliminary approval)

Note: The ~$533M attributed to End Payors reflects MDL class settlements only and does not include separate state attorney general settlements or consumer restitution funds, such as the $39.1M Apotex state fund or other state-led recoveries.

Why This Case Matters

This litigation is notable for both its scale and impact:

• Covers 100+ drugs across nearly all U.S. markets

• Supported by 49 state attorneys general +federal enforcement

• Involves allegations of price increases exceeding 1,000% in some cases

At its core, the case highlights how reduced competition in the generic drug market can significantly impact healthcare costs, especially for:

• Hospitals

• Self-funded employer

• Pharmacy providers

Recent Developments (2025–2026)

Across all tracks, the litigation continues to move forward at different speeds, with each group at a distinct stage in the process.

For Indirect Resellers (IRP), an initial filing round has been completed, and attention has shifted toward the next phase of claims administration. Several smaller IRP settlements are progressing through the approval process, including the recently filed $5.75 million Lupin settlement pending preliminary approval. At the same time, ongoing disputes in the case continue to highlight the complexity of proving damages for hospitals and providers, particularly given differences in purchasing structures and reimbursement models.

For End Payors (EPP), substantial settlements have already been reached—including major agreements such as the $200M Sun/Taro settlement and the $275M Sandoz settlement—but the claims process for these funds has not yet opened. As a result, this track represents a significant future opportunity, with timing dependent on settlement administration and resolution of outstanding legal issues, including how overlapping state and federal actions may impact distributions.

The Direct Purchaser (DPP) track is further along in the lifecycle, with multiple settlements already approved and deadlines passed across several defendants, including Sandoz, Glenmark, and Greenstone/Pfizer. This track has generated approximately $457M in recoveries to date and is moving toward distribution. MCAG does not typically participate in this track; however, if a client believes they qualify as a direct purchaser or receives a notice, they should notify MCAG for review.

Activity across the case continues to reflect ongoing challenges around class certification, individualized damages, and data requirements, all of which are influencing both timing and how claims will ultimately be evaluated. Additionally, coordination between the MDL and separate state-led actions remains an important factor, as it may impact how recoveries are allocated and distributed across claimants

What to Watch Going Forward

The next phase of this litigation will be driven by the timing of End Payor claims processes for settlements already reached, along with additional Indirect Reseller filing opportunities as more settlements move into administration. At the same time, continued activity across all tracks—including new settlements and approvals involving remaining defendants—will shape the overall recovery landscape.

Additional Resources & Next Steps

While we are currently awaiting the End Payor claims process and future Indirect Reseller filing rounds, there are other active pharmaceutical opportunities and resources to review:

• Pharmaceutical Benefit Plan Settlements (Upcoming Filing Opportunities)

• Pharmaceutical Claims: Overcoming the Challenges

  (Guidance on how to access and organize data needed to support claims)

These resources provide additional context on current pharmaceutical filing opportunities and how to prepare your data now to maximize recovery when claims open.